跳至主要内容
临床试验/NCT03337594
NCT03337594已完成不适用

Gadolinium Retention in Human Bone Tissue in Pediatric Patients: a Comparison of Dotarem Versus MultiHance MRI Contrast Agents

Donna Roberts1 个研究点 分布在 1 个国家目标入组 57 人开始时间: 2017年10月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
57
试验地点
1
主要终点
To determine the gadolinium concentration present in bone tissue in pediatric patients following a standard of care MRI with MultiHance, Dotarem, or without any exposure to contrast.

研究概览

简要总结

The purpose of this study is to compare contrast agents, Dotarem or MultiHance. The study will test to see how much of these two contrast agents are deposited in the bones or tissues of pediatric patients. The patients receiving contrast will then be compared against pediatric patients who have not received any contrast prior to cardiac surgeries.

详细描述

When injected into the body, gadolinium contrast medium makes certain tissues, abnormalities or disease processes more clearly visible on a magnetic resonance imaging (MRI) scans and therefore gadolinium based contrast agents (GBCAs) are widely used in medical imaging. Recently, new evidence suggests that following GBCA administration, gadolinium can be deposited in body tissues even in the presence of normal renal function. Therefore, it is essential to ensure that significant accumulation of free Gd3+ is not occurring in the bones of children undergoing clinical contrasted MRI scans. This is particularly important for those pediatric patients who will undergo multiple repeated MRI exams throughout their lifetime and thereby be exposed to a large cumulative dose of gadolinium contrast. As the differences in stability between the various GBCAs may be a factor in gadolinium exposure, the primary objective of this study is to assess gadolinium deposition in the bones of pediatric patients in two patient groups: 1. patients who received IV administration of gadolinium contrast agent (Dotarem) and 2. patients who received IV administration of gadolinium contrast agent (MultiHance).

Once acquired the samples will be analyzed at an off-site facility, National Institute of Standards and Technology (NIST), using standardized equipment which has been certified for measuring gadolinium concentration in contrast agent samples. A signed agreement for the transfer of non-proprietary biological material between MUSC and NIST covers the transfer of the samples.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
— 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Female or male pediatric patient (patients aged newborn to 18 years old at the time of the MRI scan).
  • Patients who require cardiac surgery for clinical purposes and meet one of the following three criteria:
  • Patients who have undergone a routine contrast-enhanced MRI using MultiHance contrast agent only for clinical purposes.
  • Patients who have undergone a routine contrast-enhanced MRI using Dotarem contrast agent only for clinical purposes.
  • Patients who have not been exposed to gadolinium-based contrast agent administration

排除标准

  • Patient with abnormal renal function (defined as eGFR MDRD<30 ml/min/1.73m2).
  • Patient previously exposed to any other type of MRI gadolinium based contrast agent either at MUSC or at an outside facility
  • Pregnant or breast feeding female patient
  • Patient with a contraindication to MRI (e.g., pacemaker, aneurysm clip, severe claustrophobia, infusion pumps, cochlear implants metallic or others according to standard practice at MUSC).

研究组 & 干预措施

Control

Pediatric patients who have not been exposed to gadolinium-based contrast agent administration and who require cardiac surgery as part of their standard clinical treatment.

干预措施: Surgery (Procedure)

Dotarem

Pediatric patients who have undergone routine contrast-enhanced MRI using only Dotarem contrast agent for clinical purposes and who require cardiac surgery as part of their standard clinical treatment.

干预措施: Pre-operative MRI with Dotarem (Drug)

Dotarem

Pediatric patients who have undergone routine contrast-enhanced MRI using only Dotarem contrast agent for clinical purposes and who require cardiac surgery as part of their standard clinical treatment.

干预措施: Surgery (Procedure)

MultiHance

Pediatric patients who have undergone routine contrast-enhanced MRI using only MultiHance contrast agent for clinical purposes and who require cardiac surgery as part of their standard clinical treatment.

干预措施: Pre-operative MRI with MultiHance (Drug)

MultiHance

Pediatric patients who have undergone routine contrast-enhanced MRI using only MultiHance contrast agent for clinical purposes and who require cardiac surgery as part of their standard clinical treatment.

干预措施: Surgery (Procedure)

结局指标

主要结局

To determine the gadolinium concentration present in bone tissue in pediatric patients following a standard of care MRI with MultiHance, Dotarem, or without any exposure to contrast.

时间窗: July 2017 to October 2022

To determine the gadolinium concentration present in sternum and rib bone tissue in 2 groups of pediatric patients requiring cardiac surgery as part of their standard clinical treatment: (1) patients who had undergone the administration of a standard clinical dose of a linear GBCA (0.1 mmol/kg IV MultiHance), and (2) patients who had undergone the administration of a standard clinical dose of a macrocyclic GBCA (0.1 mmol/kg IV Dotarem). As a control, gadolinium concentration present in sternum bone tissue will also be determined in patients who had not been exposed to GBCA administration prior to surgery.

次要结局

  • Asses the number of exposures to contrast agent as a potential confounder.(July 2017 to October 2022)

研究者

发起方
Donna Roberts
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Donna Roberts

Professor, Radiology and Radiological Science Department

Medical University of South Carolina

研究点 (1)

Loading locations...

相似试验